Please try another search
| YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|---|---|
| Growth of 1000 | 1202 | 1233 | 1095 | 1533 | 1840 | 2442 |
| Fund Return | 20.22% | 23.33% | 9.49% | 15.3% | 12.96% | 9.34% |
| Place in category | 32 | 28 | 47 | 10 | 1 | 15 |
| % in Category | 22 | 17 | 36 | 5 | 1 | 12 |
| Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
|---|---|---|---|---|---|---|
| Fidelity 500 Index Institutional Pr | 736.94B | 17.50 | 22.66 | 14.62 | ||
| Fidelity Contrafund | 163.06B | 19.86 | 31.10 | 16.58 | ||
| Fidelity Total Market Index Instl b | 122.54B | 16.87 | 21.85 | 14.04 | ||
| Fidelity Blue Chip Growth | 73.54B | 20.19 | 35.44 | 19.59 | ||
| Fidelity Growth Company | 73.1B | 25.24 | 34.26 | 20.88 |
| Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
|---|---|---|---|---|---|---|
| Vanguard Health Care Adm | 31.89B | 8.42 | 5.36 | 7.18 | ||
| T. Rowe Price Health Sciences | 6.9B | 9.95 | 5.26 | 8.72 | ||
| Fidelity Select Health Care | 6.22B | 8.87 | 6.37 | 8.90 | ||
| Vanguard Health Care Inv | 5.59B | 8.37 | 5.30 | 7.13 | ||
| T. Rowe Price Health Sciences I | 5.19B | 10.10 | 5.40 | - |
| Name | ISIN | Weight % | Last | Change % | |
|---|---|---|---|---|---|
| Eli Lilly | US5324571083 | 25.21 | 1,025.28 | +0.24% | |
| AstraZeneca ADR | US0463531089 | 11.12 | 89.10 | +0.55% | |
| Novo Nordisk ADR | US6701002056 | 6.49 | 48.26 | -1.83% | |
| UCB | BE0003739530 | 5.74 | 226.90 | +1.84% | |
| GSK plc DRC | US37733W2044 | 5.29 | 47.18 | -1.99% |
| Type | Daily | Weekly | Monthly |
|---|---|---|---|
| Moving Averages | Buy | Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review